The adenosine deaminase inhibitor deoxycoformycin was used in low doses to treat 19 patients with clinically aggressive T cell malignancy with a mature membrane phenotype. The patients comprised eight with prolymphocytic leukaemia, two with chronic lymphocytic leukaemia, four with adult T cell leukaemialymphoma, three with Sezary syndrome, and two with T cell lymphoma. Two thirds of the patients had been resistant or minimally responsive to combination chemotherapy. Complete remission was obtained in five patients (two with prolymphocytic leukaemia and one each with chronic lymphocytic leukaemia, adult T cell leukaemia-lymphoma, and Sezary syndrome) and partial remission in two others. Unmaintained complete remission lasting more than one year was seen in three patients.
Introduction
The treatment ofmature T cell malignancies has been disappointing. The median survival in two of the most common disorders (T prolymphocytic leukaemia and adult T cell leukaemia-lymphoma) is six and five months, respectively. Deoxycoformycin (Pentostatin), a potent inhibitor of adenosine deaminase, has been used to treat patients with a wide range of lymphoid neoplasms with variable success.' Differences in sensitivity among the various diseases may relate to the cellular activity of enzymes concerned with purine metabolism. The high levels of activity of adenosine deaminase in T cells as compared with B lymphocytes provided a rationale for treating T cell malignancies with deoxycoformycin.2 Other evidence, however, shows that cases with low levels of adenosine deaminase activity-for example, hairy cells and other malignant B cells-also respond to deoxycoformycin.'34 At present there is no definitive biochemical or membrane marker which identifies those cell types that are likely to respond or be resistant to deoxycoformycin. Plainly identifying such a marker would be of clinical advantage.
We report the response to deoxycoformycin in 19 patients with clinically aggressive T cell malignancies characterised by a mature (post-thymic) membrane phenotype (TdT-,CD 1-). by a CD4+ membrane phenotype and those characterised by any other membrane phenotype. The reason for this difference is not clearly understood. Deoxycoformycin inhibits adenosine deaminase, thereby causing deoxyadenosine and deoxyadenosine triphosphate to accumulate within the cell. In rapidly proliferating cells deoxyadenosine triphosphate is thought to cause cell death by inhibiting ribonucleotide reductase. In resting cells breaks appear in the strands of the deoxyribonucleic acid, possibly associated with toxicity.7 5'-Nucleotidase, which degrades deoxynucleotide triphosphates, diphosphates, and monophosphates to deoxynucleosides, may prevent the accumulation ofdeoxyadenosine triphosphate in the cell caused by deoxycoformycin.8 It seems likely, therefore, that low levels of S '-nucleotidase activity would make cells more vulnerable to the toxic effects of deoxycoformycin. Massaia et al reported that CD4+ lymphocytes have significantly less 5'-nucleotidase activity than CD8+ lymphocytes.9 Indeed, CD8+ lymphocytes have similar levels of activity to normal B cells, which are not generally killed by deoxycoformycin. This difference in levels of 5'-nucleotidase activity between CD4+ and CD8 + cells is consistent with our finding that T cell leukaemias characterised by CD4+ ,CD8-cells respond more favourably to deoxycoformycin. On the other hand, Ma et at reported that there was no significant difference in the activities of adenosine deaminase and 5'-nucleotidase between CD4+ and CD8+ cases of T cell chronic leukaemia.'0 Their series was small, however, and did not include observations on the effect of deoxycoformycin. It would clearly be of interest to measure the activities of those enzymes in a larger series of T cell malignancies to see if any correlation could be found between the activity of 5'-nucleotidase and the response to treatment with deoxycoformycin.
Patients and methods
Though the responses in our patients with mature T cell leukaemia showed a correlation with the membrane phenotype, there was none with the various cytopathological types of T cell leukaemia. These observations, if confirmed by further laboratory and clinical studies, might help define the indications for using deoxycoformycin in refractory lymphoid malignancies.
We thank Dr P O'Dwyer for helpful guidance and advice in arranging the protocol.
